Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-06-02
2010-06-01
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S230500
Reexamination Certificate
active
07728002
ABSTRACT:
A method of activating PPAR receptors in a subject, said method comprising administering to said subject an effective PPAR receptor activating amount of a pyrrolopyridine compound corresponding to formula (I):wherein R, R1, R2, R3, R4, X, Ar and n have defined meanings, or a pharmaceutically acceptable salt thereof, particularly as part of the treatment of a disorder or disease state selected from the group consisting of atherosclerosis, myocardial infarction, hypertension, and cerebral vascular disease.
REFERENCES:
patent: 2006/0100230 (2006-05-01), Bischoff et al.
patent: 2007/0117860 (2007-05-01), Dittrich-Wengenroth et al.
patent: 2007/0149514 (2007-06-01), Woltering et al.
patent: 2007/0185183 (2007-08-01), Siegel et al.
patent: WO 97/28149 (1997-08-01), None
patent: WO 98/25611 (1998-06-01), None
patent: WO 01/60807 (2001-08-01), None
patent: WO 02/071827 (2002-09-01), None
patent: WO 03/044018 (2003-05-01), None
patent: WO 2004/005253 (2004-01-01), None
patent: WO 2004/060871 (2004-07-01), None
patent: WO 2005/009958 (2005-02-01), None
patent: WO 2005/016335 (2005-02-01), None
patent: WO 2005/016881 (2005-02-01), None
patent: WO 2005/056522 (2005-06-01), None
Andrew Billin Expert Opinion on Investigational Drugs, Oct. 2008, vol. 17, No. 10, pp. 1465-1472.
International Search Report dated Jan. 18, 2007 (three (3) pages).
Recent Patents Cardiovasc Drug Discov. Jun. 2006;1(2):193-209. Role of PPAR in cardiovascular diseases. Das SK, Chakrabarti R, Metabolic Disorders Group, Dr. Reddy's Lab, Discovery Research, Bollaram Road, Miyapur, Hyderabad 500049, India. saibal99@yahoo.com.
Biochem Soc Trans. Dec. 2006;34(Pt 6):1341-6. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases, Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M. EA1046 Department of Medical Pharmacology, Faculty of Medicine, Institute of Predictive Medicine and Therapeutic Research, University Lille 2 and Lille University Hospital, 1 place de Verdun, 59045 Lille Cedex, France. email bordet@univ-lille2.fr.
Neurotherapeutics, Jul. 2008;5(3):481-9. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Landreth G, Jiang Q, Mandrekar S, Heneka M. Alzheimer Research Laboratory, Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA. gel2@case.edu.
Prog Neurobiol. Aug. 2008;85(4):433-51. Epub May 4, 2008. RAR/RXR and PPAR/RXR signaling in neurological and psychiatric diseases. Van Neerven S, Kampmann E, Mey J. Institute of Biology II, RWTH Aachen, Aachen, Germany.
J Neurochem. Jul. 2008;106(2):506-18. Epub Apr. 1, 2008. PPAR: a therapeutic target in Parkinson's disease. Chaturvedi RK, Beal MF. Department of Neurology and Neuroscience. Weill Medical College of Cornell University, New York, New York, USA.
CNS Drugs. 2008;22(1):1-14. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. Jiang Q, Heneka M, Landreth, GE Department of Neurosciences, Alzheimer Research Laboratory, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106, USA.
J Neurochem. Oct. 2008;107(2):497-509. Epub Aug. 14, 2008. PPARalpha and PPARgamma effectively protect against HIV-induced inflammatory responses in brain endothelial cells. Huang W, Rha GB, Han MJ, Eum Sy, András IE, Zhong Y, Hennig B, Toborek M. Molecular Neuroscience and Vascular Biology Laboratory, Department of Neurosurgery, University of Kentucky, Lexington, Kentucky, USA.
Barth Martine
Binet Jean
Boubia Benaïssa
Dodey Pierre
Legendre Christiane
Crowell & Moring LLP
Habte Kahsay T
Laboratoires Fournier S.A.
LandOfFree
Use of pyrrolopyridine compounds for activating PPAR... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of pyrrolopyridine compounds for activating PPAR..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of pyrrolopyridine compounds for activating PPAR... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4179110